- Vivici has formed a partnership with Ginkgo to advance
production of a sustainable and nutritious dairy protein, made via
precision fermentation.
- Ginkgo will use its Protein Production Services
and generative AI platform to deliver best-in-class
candidate strains to Vivici.
- Vivici will use the strains from this collaboration to extend
their existing range of proteins, supporting innovative specialised
nutrition companies, to bring planet-friendly nutrition to
consumers.
DELFT, Netherlands and
BOSTON, Nov. 27, 2023 /PRNewswire/ -- Vivici BV, an
innovative B2B ingredients startup company using precision
fermentation to make animal-free dairy proteins, and
Ginkgo Bioworks (NYSE: DNA), which is building the leading
platform for cell programming and biosecurity, today announced a
new partnership. Through this collaboration, Vivici will leverage
Ginkgo's extensive capabilities in strain engineering, optimisation
and performance, to develop and commercialise a next generation of
functional alternative protein.
Alternative Dairy Protein Production with Precision
Fermentation
Vivici, a startup company founded by DSM Venturing (now
part of dsm-firmenich) and Fonterra, is on a mission to meet
the world's growing need for sustainable, nutritious and great
tasting proteins. Recognizing the need for alternatives to
traditional animal agriculture, Vivici employs precision
fermentation techniques to produce animal-free dairy proteins with
microorganisms. This innovative approach not only supplements the
existing animal protein supply, but also paves the way for a more
sustainable food system in the future.
Ginkgo's Tech Solution: Strain Development at Foundry
Scale
Ginkgo plans to support Vivici by delivering optimized strains
for dairy protein production via precision fermentation. Ginkgo
intends to design and build an integrated library, screen for
strains with the best protein expression, validate and grow the
most promising hits, and then transfer the top performing strains
to Vivici for evaluation. The aim is for these strains to enable
optimal protein expression, superior functionality, and
commercial-level titers.
"We are thrilled to collaborate with Ginkgo. Ginkgo's scale and
AI-driven approach to designing strains for protein expression is a
differentiated offering. We are confident in Ginkgo's capabilities
to provide efficient, scalable strains that can support Vivici's
speed to market," said Stephan van Sint
Fiet, CEO at Vivici.
"We're so excited to support Vivici in its vision of meeting
growing demand for animal-free protein alternatives. We're here to
help Vivici deliver on the promise that precision fermentation
can lead to planet-friendly nutrition," said Kevin Madden, Senior Vice President of
Commercialization at Ginkgo Bioworks. "We believe our speed and
experience with dairy protein development, ultra high throughput
screening, and fermentation scale-up can enable Vivici to
successfully expand their current protein portfolio and bring new
solutions to market. We're eager to help Vivici enter the
market as a provider of sustainable and nutritious animal-free
protein solutions to a wide range of customers."
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell
programming, providing flexible, end-to-end services that solve
challenges for organizations across diverse markets, from food and
agriculture to pharmaceuticals to industrial and specialty
chemicals. Ginkgo's biosecurity and public health unit, Concentric
by Ginkgo, is building global infrastructure for biosecurity to
empower governments, communities, and public health leaders to
prevent, detect and respond to a wide variety of biological
threats. For more information, visit ginkgobioworks.com
and concentricbyginkgo.com, read our blog, or follow us
on social media channels such as X (formerly known as Twitter)
(@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks and
@ConcentricByGinkgo), Threads (@GinkgoBioworks)
or LinkedIn.
About Vivici
Vivici is an innovative Dutch B2B ingredients company, supplying
food and beverage brands with nutritious and sustainable
animal-free dairy proteins, made with precision fermentation.
Launching in early 2024, Vivici will bring its first product to
market, a nature-equivalent whey protein, beta-lactoglobulin. As a
B2B company Vivici will be supplying into leading innovative food
and beverage brands who are looking to bring more sustainable whey
offerings and improved animal-free consumer products to market.
For more information visit www.vivici.com, contact us via
info@vivici.com or follow us through Linkedin.
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements
within the meaning of the federal securities laws, including
statements regarding the capabilities and potential success of the
partnership and Ginkgo's cell programming platform. These
forward-looking statements generally are identified by the words
"believe," "can," "project," "potential," "expect," "anticipate,"
"estimate," "intend," "strategy," "future," "opportunity," "plan,"
"may," "should," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are predictions, projections and other statements about future
events that are based on current expectations and assumptions and,
as a result, are subject to risks and uncertainties. Many factors
could cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) volatility in the price of Ginkgo's securities due
to a variety of factors, including changes in the competitive and
highly regulated industries in which Ginkgo operates and plans to
operate, variations in performance across competitors, and changes
in laws and regulations affecting Ginkgo's business, (ii) the
ability to implement business plans, forecasts, and other
expectations, and to identify and realize additional business
opportunities, (iii) the risk of downturns in demand for products
using synthetic biology, (iv) the uncertainty regarding the demand
for passive monitoring programs and biosecurity services, (v)
changes to the biosecurity industry, including due to advancements
in technology, emerging competition and evolution in industry
demands, standards and regulations, (vi) our ability to realize the
expected benefits of merger and acquisition transactions, (vii) the
outcome of any legal proceedings against Ginkgo, including as a
result of recent acquisitions, (viii) our ability to realize the
expected benefits from and the success of our Foundry platform
programs, (ix) our ability to successfully develop engineered
cells, bioprocesses, data packages or other deliverables, and (x)
the product development or commercialization success of our
customers. The foregoing list of factors is not exhaustive. You
should carefully consider the foregoing factors and the other risks
and uncertainties described in the "Risk Factors" section of
Ginkgo's quarterly report on Form 10-Q filed with the U.S.
Securities and Exchange Commission (the "SEC") on November 8, 2023 and other documents filed by
Ginkgo from time to time with the SEC. These filings identify and
address other important risks and uncertainties that could cause
actual events and results to differ materially from those contained
in the forward-looking statements. Forward-looking statements speak
only as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Ginkgo assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Ginkgo does not give any assurance
that it will achieve its expectations.
View original
content:https://www.prnewswire.co.uk/news-releases/vivici-selects-ginkgo-bioworks-to-extend-their-range-of-novel-dairy-proteins-301997735.html